<DOC>
	<DOCNO>NCT02343393</DOCNO>
	<brief_summary>This single-blind , randomise , clinical trial assess efficacy Hydralazine Isosorbidedinitrate combination ( oral agent ) HF patient renal dysfunction .</brief_summary>
	<brief_title>Nitrates In Combination With Hydralazine cardiorEnal Syndrome ( NICHE ) Study</brief_title>
	<detailed_description>Cardiorenal syndrome ( CRS ) , renal failure heart failure ( HF ) co-exist vicious cycle , common problem great morbidity mortality . The management CRS challenge therapeutic option mutually contradictory largely empirical . Endothelial dysfunction oxidative injury recently emerge common link fail heart kidney CRS . The endothelium play obligatory role cardiovascular homeostasis , impaired endothelium-mediated nitric oxide ( NO ) bioavailability hallmark endothelial dysfunction . There high prevalence endothelial dysfunction Asian HF patient , great degree dysfunction see CRS . We hypothesise target endothelial dysfunction may improve clinical status among Asian patient CRS . Isosorbide dinitrate ( ISDN ) increase NO bioavailability . Concomitant hydralazine ( H ) therapy prevents nitrate tolerance protect NO oxidative stress-induced degradation . The synergistic combination H-ISDN think exert beneficial effect endothelium . We aim perform prospective randomise control trial ass effect H-ISDN therapy 6 month exercise capacity , endothelial function , renal function , clinical outcome quality life ( QOL ) Asian patient CRS . Specifically , hypothesise H-ISDN therapy lead improvement exercise capacity ( 6 minute walk test ( 6MWT ) ) , endothelial dysfunction ( assessed non-invasive peripheral arterial tonometry ( PAT ) ) , renal function , cardiac structure function , clinical outcome ( all-cause mortality , HF hospitalisation ) QOL Asian patient CRS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cardio-Renal Syndrome</mesh_term>
	<mesh_term>Isosorbide-5-mononitrate</mesh_term>
	<mesh_term>Isosorbide Dinitrate</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<mesh_term>Isosorbide</mesh_term>
	<criteria>1 . At least 21 year age 2 . Asian patient symptomatic HF ( regardless EF ) renal impairment ( eGFR &lt; 60ml/min/1.73m2 ) 3 . At least one hospitalisation HF preceeding year 4 . On stable ( least 1 month ) optimal medical therapy ( maximum tolerate dos ACE inhibitor ARBs , beta blocker aldosterone antagonist HFREF , optimally manage cardiovascular risk factor HFPEF ) 5 . Able complete 6 minute walk test ( 6MWT ) 6 . Able maintain systolic blood pressure â‰¥100mmHg 7 . Able provide write informed consent 1 . On chronic therapy hydralazine and/or nitrate . 2 . Known hypersensitivity hydralazine and/or nitrate 3 . Concurrent use phosphodiesterase type 5 ( PDE5 ) inhibitors 4 . Females pregnant , nursing , childbearing potential practising effective contraception 5 . Have acute myocardial infarction , unstable stable angina pectoris , cerebrovascular accident within last 3 month 6 . Have cardiac revascularisation within last 3 month likely require coronary revascularisation within study period 7 . Have cardiac arrest lifethreatening ventricular arrhythmia require intervention within 3 month 8 . Rapidly deteriorate HF ( 2 admission acute decompensated HF , due noncompliance , within 6 month ) 9. eGFR &lt; 15ml/min/1.73m2 , regular dialysis , plan dialysis within study period 10 . Serious medical condition , emergency condition , uncontrolled systemic disease medical condition , judgement investigator , prohibit patient enter potentially complete study 11 . Planned participation interventional study receive trial medication last 4 week within clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Endothelial Dysfunction</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Hydralazine-Isosorbide Dinitrate</keyword>
</DOC>